Ramosetron is a serotonin 5-HT3 receptor antagonist commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions. It is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron. Currently, ramosetron is only approved for use Japan and in certain Southeast Asian countries.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Deferasirox | The serum concentration of Ramosetron can be increased when it is combined with Deferasirox. |
| Peginterferon alfa-2b | The serum concentration of Ramosetron can be increased when it is combined with Peginterferon alfa-2b. |
| Leflunomide | The serum concentration of Ramosetron can be decreased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Ramosetron can be decreased when it is combined with Teriflunomide. |
| Buprenorphine | Ramosetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ramosetron. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ramosetron. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ramosetron. |
| Hydrocodone | Ramosetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ramosetron. |
| Magnesium sulfate | The therapeutic efficacy of Ramosetron can be increased when used in combination with Magnesium sulfate. |
| Metyrosine | Ramosetron may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ramosetron. |
| Mirtazapine | Ramosetron may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ramosetron. |
| Paraldehyde | Ramosetron may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ramosetron. |
| Pramipexole | Ramosetron may increase the sedative activities of Pramipexole. |
| Ropinirole | Ramosetron may increase the sedative activities of Ropinirole. |
| Rotigotine | Ramosetron may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Ramosetron. |
| Sodium oxybate | Ramosetron may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Ramosetron may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ramosetron. |
| Thalidomide | Ramosetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Ramosetron may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Ramosetron. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Ramosetron is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Ramosetron is combined with Phenindione. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Ramosetron is combined with Phenprocoumon. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Ramosetron is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Ramosetron is combined with Coumarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Ramosetron is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Ramosetron is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Ramosetron is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Ramosetron is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Ramosetron is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Ramosetron is combined with (S)-Warfarin. |
| Abiraterone | The serum concentration of Ramosetron can be increased when it is combined with Abiraterone. |
| Trospium | The risk or severity of constipation can be increased when Trospium is combined with Ramosetron. |
| Oxyphenonium | The risk or severity of constipation can be increased when Oxyphenonium is combined with Ramosetron. |
| Benzatropine | The risk or severity of constipation can be increased when Benzatropine is combined with Ramosetron. |
| Disopyramide | The risk or severity of constipation can be increased when Disopyramide is combined with Ramosetron. |
| Amitriptyline | The risk or severity of constipation can be increased when Amitriptyline is combined with Ramosetron. |
| Ipratropium | The risk or severity of constipation can be increased when Ipratropium is combined with Ramosetron. |
| Olanzapine | The risk or severity of constipation can be increased when Olanzapine is combined with Ramosetron. |
| Metixene | The risk or severity of constipation can be increased when Metixene is combined with Ramosetron. |
| Terfenadine | The risk or severity of constipation can be increased when Terfenadine is combined with Ramosetron. |
| Buclizine | The risk or severity of constipation can be increased when Buclizine is combined with Ramosetron. |
| Clozapine | The risk or severity of constipation can be increased when Clozapine is combined with Ramosetron. |
| Trihexyphenidyl | The risk or severity of constipation can be increased when Trihexyphenidyl is combined with Ramosetron. |
| Oxyphencyclimine | The risk or severity of constipation can be increased when Oxyphencyclimine is combined with Ramosetron. |
| Procyclidine | The risk or severity of constipation can be increased when Procyclidine is combined with Ramosetron. |
| Profenamine | The risk or severity of constipation can be increased when Profenamine is combined with Ramosetron. |
| Promazine | The risk or severity of constipation can be increased when Promazine is combined with Ramosetron. |
| Hyoscyamine | The risk or severity of constipation can be increased when Hyoscyamine is combined with Ramosetron. |
| Cyproheptadine | The risk or severity of constipation can be increased when Cyproheptadine is combined with Ramosetron. |
| Imipramine | The risk or severity of constipation can be increased when Imipramine is combined with Ramosetron. |
| Methscopolamine bromide | The risk or severity of constipation can be increased when Methscopolamine bromide is combined with Ramosetron. |
| Chlorpromazine | The risk or severity of constipation can be increased when Chlorpromazine is combined with Ramosetron. |
| Gallamine triethiodide | The risk or severity of constipation can be increased when Gallamine triethiodide is combined with Ramosetron. |
| Darifenacin | The risk or severity of constipation can be increased when Darifenacin is combined with Ramosetron. |
| Tridihexethyl | The risk or severity of constipation can be increased when Tridihexethyl is combined with Ramosetron. |
| Triflupromazine | The risk or severity of constipation can be increased when Triflupromazine is combined with Ramosetron. |
| Anisotropine methylbromide | The risk or severity of constipation can be increased when Anisotropine methylbromide is combined with Ramosetron. |
| Nortriptyline | The risk or severity of constipation can be increased when Nortriptyline is combined with Ramosetron. |
| Amoxapine | The risk or severity of constipation can be increased when Amoxapine is combined with Ramosetron. |
| Lamotrigine | The risk or severity of CNS depression can be increased when Lamotrigine is combined with Ramosetron. |
| Atropine | The risk or severity of constipation can be increased when Atropine is combined with Ramosetron. |
| Nicardipine | The risk or severity of constipation can be increased when Nicardipine is combined with Ramosetron. |
| Pirenzepine | The risk or severity of constipation can be increased when Pirenzepine is combined with Ramosetron. |
| Paroxetine | The risk or severity of constipation can be increased when Paroxetine is combined with Ramosetron. |
| Homatropine methylbromide | The risk or severity of constipation can be increased when Homatropine methylbromide is combined with Ramosetron. |
| Rocuronium | The risk or severity of constipation can be increased when Rocuronium is combined with Ramosetron. |
| Scopolamine | The risk or severity of constipation can be increased when Scopolamine is combined with Ramosetron. |
| Benzquinamide | The risk or severity of constipation can be increased when Benzquinamide is combined with Ramosetron. |
| Clidinium | The risk or severity of constipation can be increased when Clidinium is combined with Ramosetron. |
| Propiomazine | The risk or severity of constipation can be increased when Propiomazine is combined with Ramosetron. |
| Propantheline | The risk or severity of constipation can be increased when Propantheline is combined with Ramosetron. |
| Dicyclomine | The risk or severity of constipation can be increased when Dicyclomine is combined with Ramosetron. |
| Biperiden | The risk or severity of constipation can be increased when Biperiden is combined with Ramosetron. |
| Brompheniramine | The risk or severity of constipation can be increased when Brompheniramine is combined with Ramosetron. |
| Flupentixol | The risk or severity of constipation can be increased when Flupentixol is combined with Ramosetron. |
| Cocaine | The risk or severity of constipation can be increased when Cocaine is combined with Ramosetron. |
| Quinidine | The risk or severity of constipation can be increased when Quinidine is combined with Ramosetron. |
| Maprotiline | The risk or severity of constipation can be increased when Maprotiline is combined with Ramosetron. |
| Methantheline | The risk or severity of constipation can be increased when Methantheline is combined with Ramosetron. |
| Cycrimine | The risk or severity of constipation can be increased when Cycrimine is combined with Ramosetron. |
| Glycopyrronium | The risk or severity of constipation can be increased when Glycopyrronium is combined with Ramosetron. |
| Tolterodine | The risk or severity of constipation can be increased when Tolterodine is combined with Ramosetron. |
| Oxybutynin | The risk or severity of constipation can be increased when Oxybutynin is combined with Ramosetron. |
| Promethazine | The risk or severity of constipation can be increased when Promethazine is combined with Ramosetron. |
| Diphenhydramine | The risk or severity of constipation can be increased when Diphenhydramine is combined with Ramosetron. |
| Doxacurium | The risk or severity of constipation can be increased when Doxacurium is combined with Ramosetron. |
| Doxepin | The risk or severity of constipation can be increased when Doxepin is combined with Ramosetron. |
| Flavoxate | The risk or severity of constipation can be increased when Flavoxate is combined with Ramosetron. |
| Desipramine | The risk or severity of constipation can be increased when Desipramine is combined with Ramosetron. |
| Orphenadrine | Ramosetron may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Escitalopram | The risk or severity of constipation can be increased when Escitalopram is combined with Ramosetron. |
| Quetiapine | The risk or severity of constipation can be increased when Quetiapine is combined with Ramosetron. |